Rationale: Poor adherence is common in difficult-to-control asthma. Distinguishing patients with difficult-to-control asthma who respond to inhaled corticosteroids (ICS) from refractory asthma is an important clinical challenge.
Nondherence with inhaled corticosteroids (ICS) in poorly controlled severe asthma is common and associated with worse clinical outcomes (1) (2) (3) . Assessment of adherence to inhaled treatments is challenging: physician estimate and patient self-report consistently overestimate adherence compared with objective measures, and other surrogate measures, such as prescription collection records have limitations (4, 5) . The advent of novel biologic therapies targeting type-2 cytokines in severe asthma makes identification of suboptimal adherence to ICS important so the issue can be addressed before committing patients to long-term parenteral therapy. Inhaler monitoring technologies remain the gold standard in clinical trials but clinical services have been slow to embrace these in routine care. They are perceived as potentially expensive and cumbersome, and there may be concern from healthcare professionals to challenge or change nonadherent behavior.
Suppression of fractional exhaled nitric oxide (FE NO ) is an easily measured predictor of ICS response (6) (7) (8) . Directly observed ICS treatment over 7 days in subjects with a high FE NO (FE NO >45 ppb) can identify subjects with difficult-to-control severe asthma who are responsive to ICS and nonadherent with maintenance ICS treatment (FE NO suppression test [FE NO SuppT] ; see online supplement) (9) . A value of greater than or equal to 45 ppb was chosen because in subjects with severe asthma, it is associated with frequent exacerbations (10) and identifies subjects who respond to ICS treatment (6, 11) . Thus, in poorly controlled severe asthma and FE NO greater than or equal to 45 ppb, the key clinical issue is whether subjects are taking their ICS treatment effectively or whether they need treatment escalation.
The aim of this work was to assess the utility of home-based delivery of the FE NO SuppT using a remote monitoring technology enabling "directly observed therapy" to identify subjects who would achieve good asthma control with better inhaler technique or adherence to inhaled treatment. Some of the results of this study have been previously reported in the form of an abstract (12) .
Methods
This was a prospective evaluation of the FE NO SuppT in subjects attending UK severe asthma centers in the UK Refractory Asthma Stratification Program (RASP-UK) (see online supplement) (13) . The Health Research Authority Research UK Ethics Committee and the Research Leads of participating centers approved the study as a clinical service evaluation.
The inhaler monitoring technology used was the INCA device, designed to work with the Diskus inhaler (see Figure  E1 in the online supplement) (14) . This acoustic monitoring technology provides a time-stamped sound file that can be analyzed using an automated validated algorithm providing information on timing and inhaler technique (see Figure E2 ) (14) . FE NO was measured using the Niox VERO and clinical services were provided with inhaler monitoring and FE NO On return to the clinic, results from the INCA and Niox VERO were uploaded to a server using the Vitalograph IC Data Compression Utility and analyzed using the embedded sound analysis algorithm (see Figure E3) . A FE NO SuppT test was defined as previously (9) but in effect, a 42% fall in FE NO between the Day 0/Day 1 and the Day 4/Day 5 mean values equates to a positive FE NO SuppT. If a patient could use the Diskus device efficiently, they were offered the opportunity to replace their current ICS/LABA with salmeterol 50 mg/fluticasone 500 mg Diskus one inhalation twice daily with an INCA device, and were informed inhaler use was being monitored for a 1-month period (see Figure E4 ).
After 1 month of monitoring, the relationship between the FE NO SuppT and biomarker (FE NO and peripheral blood eosinophil count [PBE] ) and clinical outcomes (Asthma Control Questionnaire [ACQ-5] and spirometry) in subjects with good adherence was examined (mean adherence was 73% using biofeedback in a clinical trial setting with the INCA device, so good adherence was defined as >70% as best achievable in a real-world setting [14] ).
In parallel, a subgroup of subjects with poor asthma control despite highdose ICS/LABA treatment and FE NO less than 45 ppb at one clinical center (Belfast) (low-FE NO group) were offered INCA monitoring; if training device use was efficient after instruction, they were provided with salmeterol (50 mg/fluticasone 500 mg Diskus one inhalation twice per day) with an INCA device, to be taken twice daily for 1 month.
Statistical Analysis
Normally distributed variables are presented as mean 6 SD 
Results
Patient disposition and demographic details for high-and low-FE NO groups are shown in Figure 1 and see Figure E6 ). Subjects with a positive FE NO SuppT had similar levels of FE NO at baseline, but were younger (P , 0.001), more likely to be female (P = 0.007), had higher rates of atopic eczema (P , 0.001), higher IgE levels (P = 0.012), and were less likely to be on maintenance prednisolone (P = 0.025) ( Table 1) . There was no difference in baseline FE NO in subjects with a positive FE NO SuppT on maintenance prednisolone (median, 84 ppb; IQR, 65-111 ppb) compared with subjects not taking prednisolone (median, 92 ppb; IQR, 63-127 ppb), whereas PBE were significantly lower in subjects on prednisolone (median, 0. In subjects prescribed maintenance prednisolone, 61 (58%) had a positive FE NO SuppT and 45 (42%) had a negative test and there was an identical pattern of FE NO suppression in subjects taking prednisolone compared with subjects not taking prednisolone with no differences in baseline, Day 4, or Day 7 FE NO levels (see Figure E7 ). This was also was the case in those subjects on maintenance prednisolone with contemporaneous positive prednisolone/ cortisol levels on Day 0 (n = 59, data not shown).
PBE (Figures 3A and 3B) fell significantly from Day 0 to Day 7 in those subjects who had a positive FE NO SuppT (median difference, 20.14; 95% CI, 20.03 to 20.23; P , 0.001) but not in subjects with a negative FE NO SuppT (median difference, 0.02; 95% CI, 20.12 to 0.14; P = 0.684). This difference was more apparent for subjects not on maintenance prednisolone; after a positive FE NO SuppT from Day 0 to Day 7 (median difference, 20.21; 95% CI, 20.27 to 20.11; P , 0.001) but not in those subjects with a negative FE NO SuppT (median difference, 0.06; 95% CI, 20.25 to 0.45; P = 0.842) ( Figures 3C  and 3D ).
Post-1-Month Monitoring after FE NO SuppT
Of the subjects who successfully performed FE NO SuppT, 130 subjects agreed to proceed to monitoring for 1 month to assist with inhaled treatment usage (89 [68%] with a positive test and 41 [58%] with a negative test) ( Table 2 ). All of these subjects could use the Diskus device proficiently based on monitoring during the FE NO SuppT. Of these, one patient with a negative FE NO SuppT required rescue steroids during the monitoring month and five subjects did not complete monitoring. After performing 1-month monitoring, 54 of 85 subjects (64%) with a positive FE NO SuppT and 27 of 39 subjects (69%) with a negative FE NO SuppT had greater than or equal to 70% adherence with salmeterol 50 mg/ fluticasone 500 mg Diskus (mean adherence, 81 6 12% positive test vs. 84 6 9% negative test). For subjects who failed to achieve good adherence (>70%) during the 1-month monitoring period, both critical inhaler technique error and missed doses were common problems (mean adherence, 45 6 18%).
There was a strong relationship between Day 7 FE NO (end of FE NO SuppT) and FE NO after 1-month monitored treatment in all subjects with good adherence, and when restricting to those on maintenance prednisolone (Figure 4 ). There was also a significant reduction in PBE in subjects with a positive FE NO SuppT and good adherence who were not taking prednisolone (median difference, 20.25; 95% CI, 20.37 to 20.03; P , 0.001) ( Figure 5C ), which was not seen in those with a negative FE NO SuppT (median difference, 0.11; 95% CI, 20.13 to 0.19; P = 0.88) ( Figure 5D ). A similar trend was observed when subjects on prednisolone were included (median difference, 20.06; 95% CI, 20.17 to 0.02; P = 0.054) ( Figure  5A ); however, this just failed to reach statistical significance because, as previously noted, subjects on prednisolone had lower baseline PBE ( Figure 5 ). Again, there was no difference in subjects with a negative FE NO SuppT (median difference, 20.03; 95% CI, 20.13 to 0.08; P = 0.71) ( Figure 5B). The correlation between the Day-7 biomarkers after FE NO SuppT and post-1-month monitoring values are shown in Figure 6 (FE NO : r = 0.69; P , 0.001) (PBE: r = 0.60; P , 0.001). Post-1-month monitoring FE NO was generally lower than the Day-7 FE NO value.
Predictive Value of FE NO SuppT
We also examined the predictive value of a positive FE NO SuppT for FE NO level in subjects with good adherence after 1-month monitoring, using receiver operating characteristic analysis (see Figure E8 ). The area under the curve was 0.81 (95% CI, 0.72-0.91) and the optimal cutpoint for specificity and sensitivity was FE NO 35 ppb (in severe asthma, FE NO ,35 ppb has been shown to be associated with significantly less airway reactivity, airflow ORIGINAL ARTICLE limitation, and hyperinflation and significantly reduced emergency room and intensive care unit admissions [15] In the low-FE NO group (,45 ppb), who proceeded to monitoring for 1 month (n = 40, Table 2 ), again, despite being able to use the Diskus efficiently based on the initial dose taken in clinic and being informed and aware that they were being monitored, only 18 of 40 subjects (45%) achieved adherence greater than or equal to 70% over the 1 month monitoring period (mean adherence, 82 6 8%).
For FE NO -low subjects who failed to achieve greater than or equal to 70% adherence during the 1-month monitoring period, both critical inhaler technique error and missed doses were again common with mean adherence 35 6 21%. For those subjects who were adherent over the 1-month period (n = 18), there was a small change in FE NO 
ORIGINAL ARTICLE Lung Function and Asthma Symptom Scores
Lung function data and ACQ-5 scores at baseline and post-1-month monitoring in all subjects with good adherence are shown in Table 3 . There was a significant improvement in FEV 1 in those with a positive FE NO SuppT (mean difference, 242 ml; 95% CI, 90-395 ml) ( Table 3) which was not seen in subjects with a negative FE NO SuppT (mean difference, 122 ml; 95% CI, 2143 to 389 ml) ( Table 3 ). There was a significant improvement in ACQ-5 in both suppressor and nonsuppressor groups, which was numerically greater in subjects with a positive FE NO SuppT (mean difference, 21.2; 95% CI, 20.9 to 21.5) compared with those with a negative FE NO SuppT test (mean difference, 20.9; 95% CI, 20.4 to 21.3) and there was a significant correlation between % fall in FE NO and % improvement in ACQ-5 in all FE NO high subjects (r = 0.39; P , 0.001).
For the 14 of 54 subjects with a positive FE NO SuppT and FE NO greater than 35 ppb after 1-month monitoring, there were significant improvements in FEV 1 % (81.9 6 20.1% to 91.9 6 19.2%; P = 0.05) and ACQ5 (2.49 6 1.5 to 1.65 6 0.99; P , 0.05). Five patients had a negative FE NO SuppT and postmonitoring FE NO less than 35 ppb, and these patients generally displayed small improvements in lung function and asthma symptoms after the monitoring period. There was no change in ACQ-5 with good monitored adherence in subjects with initial FE NO less than 45 ppb (Table 3 ) and no improvement in lung function (mean difference, 2114 ml; 95% CI, 2267 to 37 ml) ( 
Discussion
This study demonstrates in subjects with difficult-to-control severe asthma and FE NO greater than or equal to 45 ppb, 65% had a positive FE NO SuppT and with effective adherence to LABA/ICS during a 1-month monitored period, there were significant improvements in symptoms and lung function and FE NO was maintained at target levels associated with reduced exacerbation, emergency room attendances, and ICU admissions (15, 16) . In contrast, among those with a negative FE NO SuppT, there was a lesser reduction in FE NO despite taking highdose ICS/LABA efficiently, with no improvement in lung function and less improvement in symptoms. The original description of the FE NO SuppT previously used physician directly observed treatment over 7 days and defined a positive FE NO SuppT for ORIGINAL ARTICLE nonadherence on poor prescription filling. The remote monitoring acoustic technology in this study effectively delivers directly observed treatment by timestamping inhaler activation and analyzing inhalation technique, which also identifies "nonintentional" nonadherence, where common critical inhaler errors prevent effective treatment. Given these patients were prescribed high-dose ICS/LABA at the time of FE NO SuppT, we believe the suppression of FE NO with effectively administered ICS/LABA treatment reflects prior inefficient ICS treatment caused by intentional and nonintentional nonadherence.
In subjects with a positive FE NO SuppT, there was also a significant fall in PBE consistent with both biomarkers being ICS responsive when adherent with monitored treatment. Composite biomarker profiling using FE NO and PBE allows better prognostic risk stratification with highest risk seen when both type 2 biomarkers are high and vice versa (17, 18) , suggesting that for subjects with a positive FE NO SuppT and resultant biomarker low profile there should be a parallel risk reduction for exacerbations. The longer term clinical and adherence outcomes for subjects characterized using FE NO SuppT in a severe asthma population are currently being studied (clinicaltrials.gov NCT02307669), but it is worth commenting that a small number of subjects, despite a good response to monitored treatment in terms of FE NO , ACQ-5, and lung function improvement, have a persistently elevated peripheral PBE. This suggests that the biologic driver of PBE in these subjects may not be as ICS responsive as FE NO , and we are also currently exploring the clinical significance of this "dissociated" biomarker profile in terms of exacerbation risk and clinical outcome (clinicaltrials.gov NCT02717689). However, our data suggest that the biomarker profile (FE NO and PBE) after 1 week of FE NO SuppT is closely related to the profile when taking optimized ICS/LABA treatment, thus facilitating identification of subjects where adherence intervention to optimize inhaled treatment may be of most value before considering treatment escalation but also potentially identifying those subjects who are likely remain biomarker high despite optimized ICS/LABA treatment and suitable for novel type 2 biologic therapies. Near maximal FE NO suppression has also been shown after 7 days of high-dose ICS treatment in mild asthma (7, 19, 20) and our data suggest that similar maximal suppression is seen in subjects with more severe asthma given the strong correlation between Day 7 FE NO post-FE NO SuppT and postmonitoring FE NO . In those subjects despite having a positive test and FE NO greater than 35 ppb after monitoring, significant falls in both FE NO was seen compared with baseline with improvements in lung function and symptom scores consistent with prior ICS nonadherence and suggesting a period of optimized inhaled treatment with clinical monitoring before treatment escalation is appropriate. The same proportion of subjects on maintenance prednisolone had positive FE NO SuppT compared with those not on prednisolone, which we believe reflects unidentified suboptimal baseline adherence to inhaled treatment and progression to oral corticosteroids. Key questions are whether this progression would have been initially prevented with optimized inhaled treatment and if these subjects can subsequently withdraw prednisolone. We are currently exploring the longer term outcome of this subgroup of patients.
The availability of novel biologic therapies targeting type 2 cytokines makes identification of suboptimal adherence to ICS important so this can be targeted before treatment escalation. An attractive proposition is to move away from imperfect surrogate measures of adherence (e.g., patient self-report, physician impression, prescription records) to using an ICSresponsive biomarker (FE NO ) as part of A strength of this data is that it occurred in a "real world" setting, bypassing the challenging aspect of engaging a nonadherent difficult-tocontrol asthma population in a clinical trial (21) . Only 16 patients were unable or forgot to perform daily FE NO during the 7-day home FE NO SuppT suggesting that this is not a major barrier to domiciliary delivery.
However, inadequate use of the monitored ICS over a 7-day period was substantially more common (33 of 49; 67%) despite being able to use the inhaler proficiently at the clinic. These data are still useful clinically because inability to take 7-day monitored treatment immediately identifies a major issue with adherence in these patients. As well as providing insight into ICS therapeutic response in a short period of time, this approach identifies subjects who can use a particular inhaler efficiently and wish to engage with a monitoring strategy to assist them with their inhaler use. However, notably 70 of 169 subjects (41%) failed to take greater than or equal to 70% or complete 1-month monitoring of inhaled treatment despite being proficient in inhaler use and keen for support, suggesting barriers to even short-term use of technological support to assist with inhaled treatment adherence. If these barriers could be identified and addressed, there could be substantial gains with optimized inhaled treatment in this poorly controlled, high-risk asthma population.
Defining the best intervention to change nonadherent behavior is out or the scope of this study, but a recent systematic review of mobile text messaging in chronic disease management confirmed improved adherence rates from 50 to 67.8% (22) , and simple reminder systems have also been shown to improve inhaled maintenance treatment in asthma (23) suggesting the gains are potentially large in this population. Multiple pharmaceutical companies are engaged with connected inhaler platforms to target adherence and utility of one of these systems aligned with exhaled nitric oxide response is currently under clinical trial (clinicaltrials. gov NCT03380429).
Formal cost-effectiveness analysis of biomarker-based assessments with adherence monitoring is required; however, this seems likely by identifying subjects who may achieve adequate asthma control without the need for treatment escalation to expensive biologic agents. Subjects with a positive FE NO SuppT were younger with more eczema and higher IgE suggesting greater ICS responsiveness in this group, although hospital admissions were equally prevalent in the high-FE NO group with positive and negative FE NO SuppT. In the NHLBI Severe Asthma Research Program, a high FE NO (.35 ppb) was associated with greater emergency room visits and hospital and ICU admissions and again in a younger, more atopic patient cohort (15) . If adherence could be satisfactorily addressed in this ICS-responsive FE NO high difficultto-control asthma population, there could potentially be a substantial impact on hospital admission rates.
In summary, we have demonstrated that and FE NO SuppT can be delivered using remote monitoring technology in routine clinical care in specialist severe asthma services in the United Kingdom. Short-term profiling of biomarker responses to ICS exposure in subjects with difficult-to-control severe asthma is a helpful part of clinical phenotyping to identify those who are likely to respond better to high-dose ICS/LABA therapy when used regularly and those who, despite good adherence with inhaled treatment, are likely to require additional treatment. In addition, this approach may be of value in identifying ICS-responsive subjects before recruitment to clinical trials investigating interventions that are "add-on" treatments to standard care (ICS/LABA) and also to studies investigating "true" ICSresistant disease. Future studies are required to identify the optimal intervention to 
